Investigate / COR
Understand Cencora, Inc.
Can Cencora keep its distribution relationships and integrate recent acquisitions while customer concentration and ownership changes at its largest customer create uncertainty?
Snapshot reviewed 2026-10-02. Source published 2026-08-05. No account needed.
AI-assisted synthesis of selected public filings, checked against the cited excerpts. Not a complete analysis.
This is a research starting point, not a buy/sell recommendation or a current valuation. New developments after these sources are not incorporated automatically.
Ownership-page coverage is not available for this company. That does not mean no tracked investor owns it.
Your research workspace / COR
Ask better questions. Keep the evidence.
Explore the available sources for Cencora, Inc., then keep what deserves another look.
01 Investor activity
Ownership coverage is unavailable—not zero owners.
02 Business evidence
Reported evidence
What does the company do?
Cencora distributes brand-name, specialty and generic pharmaceuticals, healthcare products, supplies and equipment, and related services to healthcare providers.
Latticework interpretation
What could support the case?
If management's focus on higher-margin adjacencies for manufacturers and providers succeeds alongside core distribution, the services mix could become more valuable to customers.
Latticework interpretation
What could break the case?
A small number of customers, including Walgreens and Boots, represent a large share of revenue, so losing or renewing a key relationship on less favorable terms could hurt results.
03 Questions to investigate
Open saved takeaways →Read the full company brief
1. Understand the business
Cencora distributes brand-name, specialty and generic pharmaceuticals, healthcare products, supplies and equipment, and related services to healthcare providers.
Source: Annual filing · business description ↗2. What the reported results show
Latest source: 10-Q, reporting period ended 2026-06-30. Selected reported US-GAAP/USD comparisons. The period and basis of each measure are shown separately; year-to-date cash flow is not a quarterly figure. Missing comparisons are collection gaps, not evidence that a company has no revenue or earnings.
| Measure | Current | Prior year |
|---|---|---|
| Revenue ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. | $84,754.837m | $80,663.532m |
| Operating income ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. | $1,120.217m | $867.654m |
| Net income ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. | $763.518m | $687.402m |
| Operating cash flow ↗Nine months (year to date): 2025-10-01–2026-06-30; prior 2024-10-01–2025-06-30Both values reported in the current filing. Operating cash flow is not free cash flow or a standalone solvency assessment; inspect the full statement. | $1,687.53m | $741.703m |
Comparison caveat: Operating cash flow is a fiscal nine-month total, not quarterly cash. Customer receipts, supplier payments and inventory timing materially affect it; this is not solely a profit comparison.
10-Q · latest checked financial statements and discussion ↗3. The investment debate
Latticework interpretation of the reported results—not the stated motives of any investor.
What could support the case
If management's focus on higher-margin adjacencies for manufacturers and providers succeeds alongside core distribution, the services mix could become more valuable to customers.
Supporting filing ↗The strongest caution
A small number of customers, including Walgreens and Boots, represent a large share of revenue, so losing or renewing a key relationship on less favorable terms could hurt results.
Caution evidence ↗An interesting business is not necessarily an attractive investment at today's price. Price, dilution, financing terms and a valuation range still need investigation.
Inspect the evidence behind both sides ↗4. Three questions worth investigating
Use these to guide your research, not as conclusions that have already been proved.
How exposed is Cencora to Walgreens' new ownership?
Starting evidence: New owners may seek changes to operations or to the relationship, which could affect the agreements with Walgreens, WBAD and Boots.
Investigate next: Review the contract terms, any disclosed changes, store-closure plans and notices of renewal or termination in later filings.
Read the supporting filing ↗What drives the gross profit increase, and how much is acquired?
Starting evidence: Reported gross profit growth is attributed largely to the OneOncology acquisition, higher LIFO credits and increased pharmaceutical sales, offset partly by lower antitrust settlement gains.
Investigate next: Separate acquisition contributions, LIFO credits and litigation settlement gains from underlying organic growth in segment disclosures.
Read the supporting filing ↗Is the generic mix supporting profitability?
Starting evidence: Management considers growing generic and biosimilar usage favorable because these products have historically offered greater gross profit margin opportunity than brand-name products.
Investigate next: Look for segment-level product-mix disclosure and any commentary on generic pricing or sourcing conditions.
Read the supporting filing ↗5. Decide what to do next
Worth another look? Save this company and return to the evidence. Writing a private view is optional. You do not need to decide whether to invest today.
Save is on this device. Recording a private view requires sign-in and an explicit save. Neither action subscribes you to email or automatically evaluates your thesis.